Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Clinical significance of peroxiredoxin 2 in esophageal squamous cell carcinoma and its role in cell proliferation and apoptosis in vitro

Wujun Zheng , Xiaojun Yu, Bing Bao

Department of Thoracic Surgery, The First People's Hospital of Fuyang District, Hangzhou, China;

For correspondence:- Wujun Zheng Email: fryzwj@163.com Tel:+8613967179245

Accepted: 30 June 2023 Published: 31 July 2023

Citation: Zheng W, Yu X, Bao B. Clinical significance of peroxiredoxin 2 in esophageal squamous cell carcinoma and its role in cell proliferation and apoptosis in vitro. Trop J Pharm Res 2023; 22(7):1427-1433 doi: 10.4314/tjpr.v22i7.10

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the expression of peroxiredoxin 2 (PRDX2) and its clinical significance in esophageal squamous cell carcinoma (ESCC) and its effect on the proliferation and apoptosis of ESCC cells.

Methods: The expression of PRDX2 in clinical tissues (120 samples of tumor tissues compared to 20 samples of non-tumor tissues) was determined. The tissues were divided into high-expression group (n = 56) or low-expression group (n = 64) based on the level of PRDX2. Association between PRDX2 expression and clinicopathological features of patients was further analyzed. In vitro, si-NC and si-PRDX2 were transfected into ECA-109 cells, respectively, to determine the influences of PRDX2 on the function of ESCC cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the different expressions of PRDX2 in the clinical tissues.

Results: The results from qRT-PCR indicated that PRDX2 was upregulated in ESCC tissues compared to normal control. Correlation between the expression of PRDX2 and clinical pathological data revealed that the expression of PRDX2 showed correlation with tumor differentiation, size, and clinical tumor node metastasis (TNM) stage. Modulation of PRDX2 expression by transfecting si-PRDX2 in ESCC cell lines demonstrated effective regulation of cell proliferation and apoptosis. Specifically, it was observed that cell proliferation decreased, while cell apoptosis was increased.

Conclusion: Peroxiredoxin 2 is a novel factor that plays a significant role in ESCC progression, and constitutes a potential biomarker and therapeutic target for ESCC.

Keywords: Esophageal squamous cell carcinoma (ESCC), Peroxiredoxin 2 (PRDX2), Proliferation, Apoptosis